Trial Profile
A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination With Irinotecan, in 2nd Line Patients With K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Apr 2012 Planned end date changed from 1 Jan 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 13 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Feb 2011 Array BioPharma added as company association